Burning Rock Biotech Limited (NASDAQ:BNR) Sees Large Increase in Short Interest

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 120,300 shares, an increase of 183.1% from the September 30th total of 42,500 shares. Based on an average daily volume of 27,100 shares, the short-interest ratio is currently 4.4 days. Currently, 1.4% of the shares of the stock are sold short.

Burning Rock Biotech Trading Down 1.1 %

BNR stock traded down $0.03 during midday trading on Friday, reaching $2.82. The stock had a trading volume of 15,286 shares, compared to its average volume of 13,240. Burning Rock Biotech has a 52-week low of $2.62 and a 52-week high of $11.10. The company’s fifty day simple moving average is $4.05 and its 200 day simple moving average is $6.13. The company has a market cap of $28.89 million, a price-to-earnings ratio of -0.44 and a beta of 0.13.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Thursday, August 22nd. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $18.65 million for the quarter. Burning Rock Biotech had a negative net margin of 111.25% and a negative return on equity of 74.96%.

Institutional Trading of Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC purchased a new position in Burning Rock Biotech Limited (NASDAQ:BNR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech as of its most recent SEC filing. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.